MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings
José Luís Piñana(Hospital Universitari i Politècnic La Fe), Jorge Sierra(Universitat Autònoma de Barcelona), David Valcárcel(Vall d'Hebron Hospital Universitari), Rodrigo Martino(Universitat Autònoma de Barcelona), Enric Carreras(Josep Carreras Leukaemia Research Institute), Pere Barba(Universitat Autònoma de Barcelona), Miquel Rovira, Francesc Fernández‐Avilés(Hospital Clínic de Barcelona), Salut Brunet(Institut Català d'Oncologia), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Carmen Martı́nez(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer)
Cited by 51
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k